An Observational study to characterize pharmacokinetics and pharmacogenetics of Rilpivirine in HIV infected patients

Trial Profile

An Observational study to characterize pharmacokinetics and pharmacogenetics of Rilpivirine in HIV infected patients

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 21 Nov 2016 New trial record
    • 31 Oct 2016 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top